Conditionally replicative adenovirus for gastrointestinal cancers

Research output: Contribution to journalReview articlepeer-review

10 Scopus citations


The clinical outcome of advanced gastrointestinal (GI) cancers (especially pancreatic and oesophageal cancers) is dismal, despite the advance of conventional therapeutic strategies. Cancer gene therapy is a category of new therapeutics, among which conditionally replicative adenovirus (CRAd) is one promising strategy to overcome existing obstacles of cancer gene therapy. Various CRAds have been developed for GI cancer treatment by taking advantage of the replication biology of adenovirus. Some CRAds have already been tested in clinical trials, but have fallen short of initial expectations. Concerns for clinical applicability include therapeutic potency, replication selectivity and interval end points in clinical trials. In addition, improvement of experimental animal models is needed for a deeper understanding of CRAd biology. Despite these obstacles, CRAds continue to be an exciting area of investigation with great potential for clinical utility. Further virological and oncological research will eventually lead to full realisation of the therapeutic potential of CRAds in the field of GI cancers.

Original languageEnglish (US)
Pages (from-to)1241-1250
Number of pages10
JournalExpert opinion on biological therapy
Issue number8
StatePublished - Aug 2004

Bibliographical note

Funding Information:
The author thanks Dr LP Le for his assistance. This work was supported in part by R01DK063615, DAMD17-03-1-0104 and P20CA101955.


  • Adenovirus
  • Gastrointestinal cancer
  • Gene therapy
  • Oncolytic
  • Virotherapy

Fingerprint Dive into the research topics of 'Conditionally replicative adenovirus for gastrointestinal cancers'. Together they form a unique fingerprint.

Cite this